CRISPR and Gene Editing in Neurological Disease Treatment
Gene editing technologies, particularly CRISPR-Cas systems, are transforming therapeutic strategies for neurological disorders by enabling precise modification of disease-causing genes. Advances in genome engineering now allow targeted correction of mutations associated with conditions such as Huntington’s disease, spinal muscular atrophy, and certain inherited epilepsies. Improved delivery systems, including viral vectors and lipid nanoparticles, enhance the efficiency and specificity of gene editing within neural tissues. Recent developments focus on minimizing off-target effects, improving editing accuracy, and ensuring long-term safety. Base editing and prime editing technologies further expand the scope of therapeutic possibilities without introducing double-stranded DNA breaks. Ethical oversight, regulatory frameworks, and long-term monitoring remain critical components of responsible clinical translation. Collaborative efforts between molecular biologists, neuroscientists, and biotechnology industries are accelerating progress toward gene-based neurological therapies. As precision medicine advances, gene editing holds immense promise for addressing previously untreatable brain disorders and reshaping the future of neurotherapeutics.